T. Rowe Price Associates’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.28M | Buy |
63,385
+10,599
| +20% | +$540K | ﹤0.01% | 1614 |
|
|
2025
Q4 | $2.62M | Buy |
52,786
+2,880
| +6% | +$140K | ﹤0.01% | 1637 |
|
|
2025
Q3 | $2.39M | Buy |
49,906
+2,601
| +5% | +$105K | ﹤0.01% | 1657 |
|
|
2025
Q2 | $1.49M | Buy |
47,305
+4,753
| +11% | +$152K | ﹤0.01% | 1785 |
|
|
2025
Q1 | $1.39M | Buy |
42,552
+2,124
| +5% | +$75.3K | ﹤0.01% | 1781 |
|
|
2024
Q4 | $1.46M | Sell |
40,428
-6,969
| -15% | -$245K | ﹤0.01% | 1791 |
|
|
2024
Q3 | $1.48M | Sell |
47,397
-126
| -0.3% | -$3.93K | ﹤0.01% | 1784 |
|
|
2024
Q2 | $1.27M | Sell |
47,523
-395,234
| -89% | -$11.5M | ﹤0.01% | 1783 |
|
|
2024
Q1 | $15.1M | Sell |
442,757
-2,559
| -0.6% | -$76.2K | ﹤0.01% | 1040 |
|
|
2023
Q4 | $12.9M | Sell |
445,316
-32,064
| -7% | -$850K | ﹤0.01% | 1045 |
|
|
2023
Q3 | $13.2M | Sell |
477,380
-35,624
| -7% | -$1.08M | ﹤0.01% | 1015 |
|
|
2023
Q2 | $15.4M | Buy |
513,004
+3,032
| +0.6% | +$106K | ﹤0.01% | 1003 |
|
|
2023
Q1 | $18.5M | Buy |
509,972
+619
| +0.1% | +$23.8K | ﹤0.01% | 937 |
|
|
2022
Q4 | $18.2M | Buy |
509,353
+1,490
| +0.3% | +$51.8K | ﹤0.01% | 936 |
|
|
2022
Q3 | $17.2M | Sell |
507,863
-885
| -0.2% | -$28.8K | ﹤0.01% | 948 |
|
|
2022
Q2 | $14.7M | Sell |
508,748
-7,479
| -1% | -$214K | ﹤0.01% | 1244 |
|
|
2022
Q1 | $16.7M | Sell |
516,227
-694
| -0.1% | -$21.3K | ﹤0.01% | 1278 |
|
|
2021
Q4 | $15.1M | Sell |
516,921
-5,309
| -1% | -$161K | ﹤0.01% | 1339 |
|
|
2021
Q3 | $13.9M | Sell |
522,230
-85,163
| -14% | -$2.29M | ﹤0.01% | 1378 |
|
|
2021
Q2 | $18.7M | Sell |
607,393
-990
| -0.2% | -$30.4K | ﹤0.01% | 1315 |
|
|
2021
Q1 | $15.9M | Sell |
608,383
-26,594
| -4% | -$744K | ﹤0.01% | 1325 |
|
|
2020
Q4 | $16M | Sell |
634,977
-59,138
| -9% | -$1.27M | ﹤0.01% | 1272 |
|
|
2020
Q3 | $14.5M | Sell |
694,115
-837
| -0.1% | -$19K | ﹤0.01% | 1217 |
|
|
2020
Q2 | $16.5M | Buy |
694,952
+7,633
| +1% | +$169K | ﹤0.01% | 1188 |
|
|
2020
Q1 | $12.4M | Sell |
687,319
-91,977
| -12% | -$1.93M | ﹤0.01% | 1193 |
|
|
2019
Q4 | $18.5M | Buy |
779,296
+19,671
| +3% | +$478K | ﹤0.01% | 1209 |
|
|
2019
Q3 | $20.9M | Sell |
759,625
-12,160
| -2% | -$360K | ﹤0.01% | 1138 |
|
|
2019
Q2 | $25.5M | Buy |
771,785
+1,677
| +0.2% | +$57.5K | ﹤0.01% | 1110 |
|
|
2019
Q1 | $27M | Buy |
770,108
+2,520
| +0.3% | +$93.8K | ﹤0.01% | 1082 |
|
|
2018
Q4 | $25.5M | Sell |
767,588
-6,733
| -0.9% | -$290K | ﹤0.01% | 1070 |
|
|
2018
Q3 | $39M | Buy |
774,321
+13,066
| +2% | +$645K | 0.01% | 1004 |
|
|
2018
Q2 | $45.6M | Buy |
761,255
+57,468
| +8% | +$2.98M | 0.01% | 937 |
|
|
2018
Q1 | $32.2M | Sell |
703,787
-5,431
| -0.8% | -$227K | 0.01% | 1025 |
|
|
2017
Q4 | $28.3M | Buy |
709,218
+36,537
| +5% | +$1.44M | ﹤0.01% | 1065 |
|
|
2017
Q3 | $26.9M | Buy |
672,681
+50,352
| +8% | +$2.18M | ﹤0.01% | 1079 |
|
|
2017
Q2 | $26.8M | Buy |
622,329
+37,468
| +6% | +$1.33M | ﹤0.01% | 1067 |
|
|
2017
Q1 | $18.3M | Buy |
584,861
+271,216
| +86% | +$7.27M | ﹤0.01% | 1192 |
|
|
2016
Q4 | $7.92M | Buy |
313,645
+290,960
| +1,283% | +$6.5M | ﹤0.01% | 1353 |
|
|
2016
Q3 | $561K | Sell |
22,685
-26,175
| -54% | -$592K | ﹤0.01% | 1965 |
|
|
2016
Q2 | $995K | Buy |
48,860
+4,850
| +11% | +$86K | ﹤0.01% | 1711 |
|
|
2016
Q1 | $671K | Sell |
44,010
-434,420
| -91% | -$5.67M | ﹤0.01% | 1854 |
|
|
2015
Q4 | $6.43M | Sell |
478,430
-500,235
| -51% | -$7.74M | ﹤0.01% | 1378 |
|
|
2015
Q3 | $13.7M | Sell |
978,665
-95,584
| -9% | -$1.78M | ﹤0.01% | 1222 |
|
|
2015
Q2 | $18.2M | Buy |
1,074,249
+12,799
| +1% | +$182K | ﹤0.01% | 1165 |
|
|
2015
Q1 | $12.8M | Sell |
1,061,450
-360,382
| -25% | -$3.41M | ﹤0.01% | 1264 |
|
|
2014
Q4 | $11.8M | Sell |
1,421,832
-935,818
| -40% | -$7.86M | ﹤0.01% | 1274 |
|
|
2014
Q3 | $20.5M | Sell |
2,357,650
-1,071,240
| -31% | -$9.68M | ﹤0.01% | 1106 |
|
|
2014
Q2 | $37.5M | Sell |
3,428,890
-757,661
| -18% | -$6.75M | 0.01% | 949 |
|
|
2014
Q1 | $37.4M | Sell |
4,186,551
-176,249
| -4% | -$1.62M | 0.01% | 942 |
|
|
2013
Q4 | $32.9M | Sell |
4,362,800
-141,800
| -3% | -$991K | 0.01% | 958 |
|
|
2013
Q3 | $33M | Sell |
4,504,600
-235,100
| -5% | -$1.58M | 0.01% | 951 |
|
|
2013
Q2 | $30.5M | Buy |
+4,739,700
| New | +$27.9M | 0.01% | 952 |
|
Other funds holding SUPN
VPM
VCM
NAMI
AC
T. Rowe Price Associates's SUPN Position: Q1 2026 in Review
T. Rowe Price Associates increased its Supernus Pharmaceuticals (SUPN) stake by 20% in Q1 2026, buying an estimated $540K and bringing the position to 63,385 shares worth $3.28M. The position accounts for ﹤0.01% of the portfolio, ranked #1614.
T. Rowe Price Associates first reported a position in SUPN in Q2 2013 and has held it in 52 quarters since. The position peaked at $45.6M in Q2 2018. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.
- T. Rowe Price Associates held 63,385 shares of Supernus Pharmaceuticals worth $3.28M as of Q1 2026.
- T. Rowe Price Associates bought 10,599 Supernus Pharmaceuticals shares in Q1 2026, an estimated $540K.
- Supernus Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1614 holding.
- T. Rowe Price Associates first reported a position in Supernus Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- T. Rowe Price Associates's Supernus Pharmaceuticals position peaked at $45.6M in Q2 2018.
- 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.